{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:42:30Z","timestamp":1794271350869,"version":"4.9.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.neurot.2024.e00378","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T17:34:15Z","timestamp":1725298455000},"page":"e00378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)"],"prefix":"10.1016","volume":"21","author":[{"suffix":"Jr.","given":"James F.","family":"Howard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuan","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Korobko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Smilowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fien","family":"Gistelinck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Steeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Noukens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Van Hoorick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Podhorna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Borgions","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuebing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiaki","family":"Utsugisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Wiendl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan L.","family":"De Bleecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Mantegazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2024.e00378_bib1","first-page":"265","article-title":"New pathways and therapeutic targets in autoimmune myasthenia gravis","volume":"5","author":"Behin","year":"2018","journal-title":"J\u00a0Neuromuscul Dis"},{"key":"10.1016\/j.neurot.2024.e00378_bib2","first-page":"82","article-title":"Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3","volume":"67","author":"R\u00f8dgaard","year":"1987","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.neurot.2024.e00378_bib3","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.neurot.2024.e00378_bib4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.neurot.2024.e00378_bib5","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3389\/fneur.2020.00604","article-title":"A\u00a0practical approach to managing patients with myasthenia gravis-opinions and a review of the literature","volume":"11","author":"Farrugia","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurot.2024.e00378_bib6","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.neurot.2024.e00378_bib7","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/nbt1143","article-title":"Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels","volume":"23","author":"Vaccaro","year":"2005","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.neurot.2024.e00378_bib8","doi-asserted-by":"crossref","first-page":"E2862","DOI":"10.1073\/pnas.1618291114","article-title":"Hepatic FcRn regulates albumin homeostasis and susceptibility to liver injury","volume":"114","author":"Pyzik","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurot.2024.e00378_bib9","doi-asserted-by":"crossref","first-page":"118074","DOI":"10.1016\/j.jns.2021.118074","article-title":"IgG regulation through FcRn blocking: a novel mechanism for the treatment of myasthenia gravis","volume":"430","author":"Wolfe","year":"2021","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.neurot.2024.e00378_bib10","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2024.e00378_bib11","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bjd.20782","article-title":"Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial","volume":"186","author":"Goebeler","year":"2022","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.neurot.2024.e00378_bib12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal Fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.neurot.2024.e00378_bib13","series-title":"VYVGART (efgartigimod alfa-fcab) Prescribing Information 2021 [online]. Available at:","year":"2021"},{"key":"10.1016\/j.neurot.2024.e00378_bib14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","article-title":"Efgartigimod: first approval","volume":"82","author":"Heo","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.neurot.2024.e00378_bib16","unstructured":"argenx. argenx announces VYVGART (efgartigimod alfa) authorized for sale by Health Canada for generalized myasthenia gravis [online]. Available at: https:\/\/www.argenx.com\/news\/argenx-announces-vyvgart-efgartigimod-alfa-authorized-sale-health-canada-generalized. Accessed October 25, 2023."},{"key":"10.1016\/j.neurot.2024.e00378_bib17","unstructured":"Zai Lab. Zai Lab and argenx announce approval of VYVGART\u00ae (efgartigimod alfa injection) for generalized myasthenia gravis in China [online]. Available at: https:\/\/ir.zailaboratory.com\/news-releases\/news-release-details\/zai-lab-and-argenx-announce-approval-vyvgartr-efgartigimod-alfa. Accessed October 25, 2023."},{"key":"10.1016\/j.neurot.2024.e00378_bib18","unstructured":"ClinicalTrials.gov. An efficacy and safety study of ARGX-113 in patients with myasthenia gravis who have generalized muscle weakness (ADAPT) [online]. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03669588. Accessed October 25, 2023."},{"key":"10.1016\/j.neurot.2024.e00378_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1284444","article-title":"Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis","volume":"14","author":"Howard","year":"2024","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurot.2024.e00378_bib20","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/10717544.2018.1551442","article-title":"ENHANZE\u00ae drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20","volume":"26","author":"Locke","year":"2019","journal-title":"Drug Deliv"},{"key":"10.1016\/j.neurot.2024.e00378_bib21","unstructured":"ClinicalTrials.gov. A phase 1 study to compare the safety and effect of efgartigimod as an intravenous infusion with the effect of efgartigimod as a subcutaneous injection in healthy volunteers [online]. Available at: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04564066. Accessed October 25, 2023."},{"key":"10.1016\/j.neurot.2024.e00378_bib22","unstructured":"Casey J, Li G, Li Y, et\u00a0al. Dose selection and clinical development of efgartigimod PH20 SC in patients with gMG. Presented at: American Academy of Neurology (AAN) Annual Meeting; April 22-27, 2023; Boston, MA."},{"key":"10.1016\/j.neurot.2024.e00378_bib23","unstructured":"VYVGART\u00ae HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) injection, for subcutaneous use Prescribing Information [online]. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761304s000lbl.pdf. Accessed October 25, 2023."},{"key":"10.1016\/j.neurot.2024.e00378_bib24","unstructured":"ClinicalTrials.gov. Evaluating the pharmacodynamic noninferiority of efgartigimod PH20 SC administered subcutaneously as compared to efgartigimod administered intravenously in patients with generalized myasthenia gravis (ADAPTsc) [online]. Available at: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04735432. Accessed October 25, 2023."},{"key":"10.1016\/j.neurot.2024.e00378_bib25","unstructured":"ClinicalTrials.gov. Evaluating the long-term safety and tolerability of efgartigimod PH20 SC administered subcutaneously in patients with generalized myasthenia gravis (ADAPTSC+) [online]. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04818671. Accessed October 25, 2023."},{"key":"10.1016\/j.neurot.2024.e00378_bib26","unstructured":"ClinicalTrials.gov. A safety and tolerability study of ARGX-113 in patients with myasthenia gravis who have generalized muscle weakness (ADAPT+) [online]. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03770403. Accessed October 25, 2023."},{"key":"10.1016\/j.neurot.2024.e00378_bib27","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/mus.22140","article-title":"MG Composite and MG-QOL15 study group. MG-ADL: still a relevant outcome measure","volume":"44","author":"Muppidi","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.neurot.2024.e00378_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.596382","article-title":"Outcome measures in clinical trials of patients with myasthenia gravis","volume":"11","author":"Thomsen","year":"2020","journal-title":"Front Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2024.e00378_bib29","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/mus.27476","article-title":"Utilization of MG-ADL in myasthenia gravis clinical research and care","volume":"65","author":"Muppidi","year":"2022","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.neurot.2024.e00378_bib30","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2024.e00378_bib31","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12817","article-title":"Injection site reactions with the use of biological agents","volume":"32","author":"Thomaidou","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.neurot.2024.e00378_bib32","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1080\/17425247.2021.1981286","article-title":"Safety of recombinant human hyaluronidase PH20 for subcutaneous drug delivery","volume":"18","author":"Knowles","year":"2021","journal-title":"Expert Opin Drug Deliv"},{"issue":"8","key":"10.1016\/j.neurot.2024.e00378_bib33","first-page":"3862","article-title":"Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension","volume":"270","author":"Meisel","year":"2023","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.neurot.2024.e00378_bib34","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/ene.14153","article-title":"Serious infections in patients with myasthenia gravis: population-based cohort study","volume":"27","author":"Kassardjian","year":"2020","journal-title":"Eur J Neurol"},{"issue":"17","key":"10.1016\/j.neurot.2024.e00378_bib35","first-page":"P10","article-title":"Analysis of serious infections and malignancy risk in myasthenia gravis: a US claims database study","volume":"102","author":"Podhorna","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2024.e00378_bib36","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fimmu.2015.00176","article-title":"Fully human monoclonal antibody inhibitors of the neonatal Fc receptor reduce circulating IgG in non-human primates","volume":"6","author":"Nixon","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurot.2024.e00378_bib37","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1080\/08916934.2022.2104261","article-title":"Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis","volume":"55","author":"Guptill","year":"2022","journal-title":"Autoimmunity"},{"key":"10.1016\/j.neurot.2024.e00378_bib38","doi-asserted-by":"crossref","first-page":"892534","DOI":"10.3389\/fimmu.2022.892534","article-title":"Clinical significance of serum albumin and implications of FcRn inhibitor treatment in IgG-mediated autoimmune disorders","volume":"13","author":"Ward","year":"2022","journal-title":"Front Immunol"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747924000643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747924000643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:08:27Z","timestamp":1762560507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747924000643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1878747924000643"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2024.e00378","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2024.e00378","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00378"}}